XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event)
Per Pfeiffer, MD
Principal Investigator
Department of Oncology, Odense University Hospital
Denmark: Central Scientific Ethical Committee
XELOX III
NCT00212615
February 2004
October 2008
Name | Location |
---|